Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision
Open accessThe DOI matches its Crossref record; 183 of the 192 references it cites were found in a registry or an index; 48 of the 182 sources its claims cite were checked for support.
Abstract
Fungal diseases kill more than 1.5 million and affect over a billion people. However, they are still a neglected topic by public health authorities even though most deaths from fungal diseases are avoidable. Serious fungal infections occur as a consequence of other health problems including asthma, AIDS, cancer, organ transplantation and corticosteroid therapies. Early accurate diagnosis allows prompt antifungal therapy; however this is often delayed or unavailable leading to death, serious chronic illness or blindness. Recent global estimates have found 3,000,000 cases of chronic pulmonary aspergillosis, ~223,100 cases of cryptococcal meningitis complicating HIV/AIDS, ~700,000 cases of invasive candidiasis, ~500,000 cases of Pneumocystis jirovecii pneumonia, ~250,000 cases of invasive aspergillosis, ~100,000 cases of disseminated histoplasmosis, over 10,000,000 cases of fungal asthma and ~1,000,000 cases of fungal keratitis occur annually. Since 2013, the Leading International Fungal Education (LIFE) portal has facilitated the estimation of the burden of serious fungal infections country by country for over 5.7 billion people (>80% of the world’s population). These studies have shown differences in the global burden between countries, within regions of the same country and between at risk populations. Here we interrogate the accuracy of these fungal infection burden estimates in the 43 published papers within the LIFE initiative.
Overview
CoChat Summary
TL;DR
This review interrogates the accuracy of global and multi-national estimates of serious fungal disease burden generated through the Leading International Fungal Education (LIFE) initiative. It summarizes estimates from 43 published country reports and highlights wide variation, data gaps, and likely underestimation of fungal disease burden.
Key findings
- Recent global estimates include 3,000,000 cases of chronic pulmonary aspergillosis, ~223,100 cases of cryptococcal meningitis complicating HIV/AIDS, ~700,000 cases of invasive candidiasis, ~500,000 cases of *Pneumocystis jirovecii* pneumonia, ~250,000 cases of invasive aspergillosis, ~100,000 cases of disseminated histoplasmosis, over 10,000,000 cases of fungal asthma, and ~1,000,000 cases of fungal keratitis annually.
- Across LIFE country papers, candidaemia burden was 159,253 cases in 39 countries, invasive aspergillosis was 81,927 cases in 40 countries, and *Pneumocystis jirovecii* pneumonia was 133,487 cases in 40 papers; the highest candidaemia prevalence was reported in Pakistan (38,795 cases, 21 per 100,000).
- Chronic pulmonary aspergillosis estimates were highest in India (209,147) and Nigeria (120,753), with an overall incidence of 22 cases per 100,000 (14.2–30.59 95% CI); ABPA was estimated at 3,550,157 cases and SAFS at 4,125,428 cases across 43 countries.
- Tinea capitis was estimated at 21,073,423 cases in just 16 countries, with Nigeria alone accounting for 15,581,400 cases; global recurrent vulvovaginal candidiasis prevalence was estimated at about 134,000,000 cases.
Methods
- Narrative review of 43 published papers within the LIFE initiative, covering >2000 million people (29% of the world population), with the LIFE portal having facilitated estimates for over 5.7 billion people (>80% of the world’s population).
- The paper describes how country-level burden estimates were derived for specific fungal diseases, using published epidemiological data, modelling assumptions, and at-risk population denominators.
- Main analysis is descriptive and comparative: it aggregates country estimates, examines differences by region, country, and at-risk group, and discusses strengths and weaknesses of the estimation methods.
Limitations
- The paper states that a precise estimate of global prevalence and incidence for each fungal infection remains unknown, and data are scanty in most countries, especially in the developing world.
- It states that knowledge is impaired by lack of regular national surveillance, no obligatory reporting of fungal diseases, poor clinician suspicion outside specialised units, poor diagnostic test performance, and few well-designed published studies; estimates are not intended as a substitute for high-quality epidemiological study or comprehensive surveillance.
- It also states that comparisons across countries are difficult because recent local epidemiological data were available for only some countries, data quality varies, not all institutions report infections, and many low- and low-middle-income countries lack blood culture systems; the text makes evident that country estimates rely on heterogeneous assumptions and uniform rates in places, such as 5 per 100,000 for candidaemia when local data were unavailable and 6% for recurrent vulvovaginal candidiasis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
33 Valid · 8 Not valid · 70 Not checked · 75 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“In particular, resistance to fluconazole is common [30,43,44]”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
What the sources say
- Not checked — no full text of the sourcecites [30] Arendrup M.C. Candida and Candidaemia: Susceptibility and Epidemiology Dan. Med. J. 2013 60 1 32 24192246
- Disputedcites [43] Hii I.M. Chang H.L. Lin L.C. Lee Y.L. Liu Y.M. Liu C.E. Chen C.H. Cheng Y.R. Chang C.Y. Changing epidemiology of candidemia in a medical center in middle Taiwan J. Microbiol. Immunol. Infect. 2015 48 306 315 10.1016/j.jmii.2013.08.017 24113067 sourceExperimental — accuracy not yet measured
The Discussion reports an overall fluconazole resistance rate of 4.95% among the clinical Candida isolates, contrary to the unqualified claim that resistance is common. The Antifungal susceptibility section distinguishes resistance from reduced susceptibility: only 4.4% of C. glabrata isolates were resistant, although 66.7% were dose-dependent susceptible. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Supportedcites [44] Al Thaqafi A.H.O. Farahat F.M. Al Harbi M.I. Al Amri A.F.W. Perfect J.R. Predictors and outcomes of Candida bloodstream infection: Eight-year surveillance, western Saudi Arabia Int. J. Infect. Dis. 2014 21 5 9 10.1016/j.ijid.2013.12.012 24468816 source
The Discussion describes a high level of fluconazole resistance as alarming. The Results report low in vitro susceptibility among Candida bloodstream isolates in the hospital studied, supporting the claim in that setting. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Modelling with existing outcome data shows that mortality associated with these priority fungal diseases concurrently with the Joint United Nations Program on HIV/AIDS (UNAIDS) 90-90-90 campaign could save over 1.6 million lives of persons living with HIV globally over the next five years [2].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 1. Introduction
What the sources say
- Supportedcites [2] Denning D.W. Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500,000 by 2020 to be realized Philos. Trans. R. Soc. B 2016 371 10.1098/rstb.2015.0468 28080991 PMC5095544 source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The burden of infectious (all-cause, including fungal) keratitis in Mexico was estimated based on the prevalence of reported in China (0.148%) [150].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.6. Fungal Keratitis
What the sources say
- Supportedcites [150] Cao J. Yang Y. Yang W. Wu R. Xiao X. Yuan J. Xing Y. Tan X. Prevalence of infectious keratitis in Central China BMC Ophthalmol. 2014 14 1 6 10.1186/1471-2415-14-43 24690368 PMC3976152 source
The Abstract Results report an infectious keratitis prevalence of 0.148% in Central China and separately include fungal keratitis among its causes. The Mexico estimate is the citing authors’ use of that figure, not a result attributed to this source. (LLM, conf=0.92)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Since 2013, the Leading International Fungal Education (LIFE) portal has facilitated the estimation of the burden of serious fungal infections country by country for over 5.7 billion people (>80% of the world’s population).”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > Abstract
What the sources say
- Partly supportedcites [14] Denning D.W. Calling upon all public health mycologists Eur. J. Clin. Microbiol. Infect. Dis. 2017 36 923 924 10.1007/s10096-017-2909-8 28150046 sourceExperimental — accuracy not yet measured
The paper describes systematic country-by-country estimates of serious fungal infections and links to the LIFE site for completed estimates (p. 1). It does not state that the portal facilitated this work since 2013 or that the estimates covered over 5.7 billion people (>80% of the world’s population); its stated figure of 883 million people refers only to the current 14-country series (p. 1). (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“HIV/AIDS pandemic, tuberculosis, chronic obstructive pulmonary disease (COPD), asthma and the increasing incidence of cancers are the major drivers of fungal infections in both developed and developing countries globally [1,2,3,4,5,6].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 1. Introduction
What the sources say
- Not checked — no full text of the sourcecites [1] Brown G.D. Denning D.W. Gow N.A.R. Levitz S.M. Netea M.G. White T.C. Hidden Killers: Human Fungal Infections Sci. Transl. Med. 2012 4 1 9 10.1126/scitranslmed.3004404 23253612 source
- Partly supportedcites [2] Denning D.W. Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500,000 by 2020 to be realized Philos. Trans. R. Soc. B 2016 371 10.1098/rstb.2015.0468 28080991 PMC5095544 sourceExperimental — accuracy not yet measured
The Introduction identifies major fungal diseases complicating HIV, and the section on chronic pulmonary aspergillosis complicating tuberculosis in HIV-positive patients names TB and COPD as underlying pulmonary disorders (page unavailable). The paper does not identify asthma or increasing cancer incidence as drivers, nor does it establish that the listed conditions are the major drivers of fungal infections globally across developed and developing countries. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [3] Armstrong-James D. Meintjes G. Brown G.D. A neglected epidemic: Fungal infections in HIV/AIDS Trends Microbiol. 2014 22 120 127 10.1016/j.tim.2014.01.001 24530175 source
- Not checked — no full text of the sourcecites [4] Guinea J. Torres-Narbona M. Gijón P. Muñoz P. Pozo F. Peláez T. de Miguel J. Bouza E. Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: Incidence, risk factors, and outcome Clin. Microbiol. Infect. 2010 16 870 877 10.1111/j.1469-0691.2009.03015.x 19906275 source
- Not checked — no full text of the sourcecites [5] Marr K.A. Carter R.A. Boeckh M. Martin P. Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: Changes in epidemiology and risk factors Blood 2002 100 4358 4366 10.1182/blood-2002-05-1496 12393425 source
- Not checked — no full text of the sourcecites [6] Limper A.H. Adenis A. Le T. Harrison T.S. Fungal infections in HIV/AIDS Lancet Infect. Dis. 2017 10.1016/S1473-3099(17)30303-1 28774701 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
52 more claims · 6 with their cited sources checked
Create a free account to see all 186 claims and to verify the 39 references still open.
- Probably not a substantial claim. 80
- It may state two separate claims as one. 82
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although the target organ of A. fumigatus is the lungs, Aspergillus is known to be angiotropic and has an affinity for host vasculature. As growing hyphae penetrate pulmonary tissues, they can invade the endothelial lining of nearby blood vessels and break off into circulation, causing sepsis and dissemination accompanied by thrombosis, hemorrhagic infarction and invasion of distant organs [8, 164”
From Mechanisms of fungal dissemination (2021) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fungal pathogens are responsible for at least 13 million infections and 1.5 million deaths globally per year, primarily in those with some compromised immune function [1].”
From Prevalence and Healthcare Burden of Fungal Infections in the United States, 2018 (2022) · cites this paper as [1]
Experimental — accuracy not yet measuredIn the citing paper
“In healthy individuals, these conidia are rapidly cleared, but in the case of immunocompromised patients, conidia can germinate and develop filamentous hyphae [1, 166]. This fungal growth can result in invasive aspergillosis: a severe and aggressive fungal disease characterized by tissue damage, necrosis and hypoxia [8, 164, 167].”
From Mechanisms of fungal dissemination (2021) · cites this paper as [8]
In the citing paper
“Candida albicans the primary species responsible for mucosal disease”
From Acquisition of cross-azole tolerance and aneuploidy in Candida albicans strains evolved to posaconazole (2022) · cites this paper as Bongomin et al. 2017
In the citing paper
“Deep-seated candidiasis, arising from direct inoculation or hematogenous dissemination of Candida into normally sterile body sites, is often difficult to diagnose and may affect a population as large as that of candidemia [4,5,6].”
From Treatment of Invasive Candidiasis: A Narrative Review (2018) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“28,447 [2.5% of 1,136,092] (62 per 100,000) patients with ABPA”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“37,491 [3.33% of 1,136,092] (37.5 per 100,000) with severe asthma with fungal sensitisation (SAFS)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“Average incidence is 154 cases per 100,000 (SD ± 654)”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“the highest incidence rates reported in United Kingdom (654 per 100,000)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
“The total burden of candidaemia is 159,253 cases across these 39 countries with available data.”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
“Europe (n = 1 country, 420,549 cases)”
Citations
Cites
Vos, T., Flaxman, A. D., Naghavi, M., Lozano, R., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., Aboyans, V., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61729-2 · Cited by 8,291
Wang, H., Naghavi, M., Allen, C., Barber, R. M., Bhutta, Z. A., Carter, A., Casey, D. C., Charlson, F. J., Chen, A. Z., Coates, M. M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31012-1 · Cited by 6,596
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496 · cited 1×
“Candidaemia is the most common form of invasive candidiasis associated with an unacceptably high mortality rates in excess of 40% even with the introduction of newer antifungal agents [30,32,33].”
BackgroundHidden Killers: Human Fungal Infections
Brown, G. D., Denning, D. W., Gow, N. A. R., Levitz, S. M., Netea, M. G., & White, T. C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004404 · Cited by 4,284 · cited 1×
“Pneumocystis jirovecii pneumonia is emerging as a leading cause of infection in HIV/AIDS patients [1].”
BackgroundSelf-citationGlobal burden of disease of HIV-associated cryptococcal meningitis: an updated analysis
Rajasingham, R., Smith, R. M., Park, B. J., Jarvis, J. N., Govender, N. P., Chiller, T. M., Denning, D. W., Loyse, A., & Boulware, D. R. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30243-8 · Cited by 1,861 · cited 1×
“[8], Fungal Infection Trust [12], Global Action Fund for Fungal Infection (GAFFI) Roadmap [9], and van de Sande [13].”
BackgroundSelf-citationGlobal asthma prevalence in adults: findings from the cross-sectional world health survey
To, T., Stanojevic, S., Moores, G., Gershon, A. S., Bateman, E. D., Cruz, A. A., & Boulet, L.-P. (2012) · BMC Public Health · doi:10.1186/1471-2458-12-204 · Cited by 1,521 · cited 1×
“6% respectively among individuals aged 18 to 45 years [142].”
BackgroundKullberg, B. J., & Arendrup, M. C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1315399 · Cited by 1,315 · cited 1×
“Candidaemia is the most common form of invasive candidiasis associated with an unacceptably high mortality rates in excess of 40% even with the introduction of newer antifungal agents [30,32,33].”
BackgroundSobel, J. D. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60917-9 · Cited by 1,270
Marr, K. A., Carter, R. A., Boeckh, M., Martin, P., & Corey, L. (2002) · Blood · doi:10.1182/blood-2002-05-1496 · Cited by 957
(2006) · PubMed · Cited by 906
Research works printed but not linked: 6
- Denning D.W. Global fungal Burden Mycoses 2013 56 13
- The Fungal Infection Trust How common are fungal diseases? Proceedings of the Fungal Research Trust 20th Anniversary Meeting London, UK 18 June 2011 updated August 2017, London, UK 2017 Available online: http://www.fungalinfectiontrust.org/wp-content/uploads/2015/12/How-Common-are-Fungal-Diseases-v12.2.pdf (accessed on 12 September 2017)
- Jayasekera P.I. Denning D. Perera P. Fernando A. Kudavidanage S. The burden of serious fungal infections in Sri Lanka Mycoses 2013 56 103
- Beardsley J. Denning D. Chau N. Crump J. Day J. Estimating the burden of fungal diseases in Vietnam Eur. Conf. Clin. Microbiol. Infect. Dis. Published Online First: 2014 Available online: http://eccmid.meetingxpert.net/ECCMID_699/poster_108496/program.aspx/anchor108496 (accessed on 31 August 2017)
- Gugnani H.C. Denning D.W. Rahim R. Sadat A. Belal M. Mahbub M.S. Medina N. Samayoa B. Lau-Bonilla D. Denning D.W. Burden of serious fungal infections in Bangladesh Eur. J. Clin. Microbiol. Infect. Dis. 2017 36 965 969 10.1007/s10096-017-2921-z 28161744 · DOI · Paper page
- Samayoa B. Isern V. Serra L. Rivera B.E. Nikiforov M. Arathoon E. Samayoa C. Vallès X. Prieto L. Álvarez C. Preliminary results of a prospective cohort of HIV+ patients in Guatemala Proceedings of the XVIII International AIDS Conference Vienna, Austria 18–23 July 2010
Cited by
Items 2,301–2,400 of 2,932
Chander, J., Singh, H., & Joshi, D. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00190-0 · Cited by 2
Bepary, S., Biswas, B. K., Ghosh, P., Haque, M. A., & Tran, Q. D. (2021) · Journal of Molecular Docking · doi:10.33084/jmd.v1i2.3142 · Cited by 2
Sabdono, A., Radjasa, O. K., Trianto, A., Korshunova, T., Martynov, A. V., & Sibero, M. T. (2022) · F1000Research · doi:10.12688/f1000research.108857.1 · Cited by 6
“However, they are still a neglected topic by public health authorities even though most casualties from skin diseases are avoidable (Alfonso et al., 2017; Bongomin et al., 2017).”
Background(2022) · European Journal of Medical and Health Sciences · doi:10.34104/ejmhs.022.01380144 · Cited by 2
Screening for pulmonary mycosis
Gupta, R., Singla, P., Goel, N., et al. (2021) · Egyptian Journal of Chest Diseases and Tuberculosis · doi:10.4103/ejcdt.ejcdt_28_20 · Cited by 1
Antifungal Potency of Green-Fabricated Nanoparticles-An Overview of Recent Advances
(2023) · International Journal of Agriculture and Biosciences · doi:10.47278/book.oht/2023.67 · Cited by 1
Kamikawa, C. M., & Vicentini, A. P. (2022) · REVISTA DO INSTITUTO ADOLFO LUTZ · doi:10.53393/rial.2022.v81.37165 · Cited by 2
“The three main components of the cell wall, shared by most clinically important fungal species, are: β-glucans (which are polymers of glycose), especially β-(1,3)-glucans; chitin (which is a polymer of N-acetylglucosamine) and mananas (which are chains of several hundred mannose molecules that are added to fungal prot…”
BackgroundC., F., Rodríguez, J. A., Muñoz, L. M., Apráez-Ippolito, G., & Arteaga, L. R. V. (2023) · Biomédica · doi:10.7705/biomedica.6793 · Cited by 1
“En Europa, el agente causal más común en humanos es M. canis , que se distribuye principalmente en el Mediterráneo y, también, en países como Austria, Hungría, Alemania y Polonia (11,12).”
BackgroundIdentification and Antifungal Resistance among Candida species from the Genitourinary Tract
Unegbu, V. N. (2022) · Open Access Journal of Mycology & Mycological Sciences · doi:10.23880/oajmms-16000165
Uses and Advantages of CRISPR/Cas Genetic Edition in YeastsPreprint
Amado, D., Vélez, N., Ceballos-Garzón, A., Monroy, J., & Parra‐Giraldo, C. M. (2018) · Preprints.org · doi:10.20944/preprints201812.0001.v1
“Candida Sp is a genus of yeasts and is the most common cause of fungal infections worldwide; This 83 opportunistic infection has a global incidence of around 700,000 cases per year [4].”
BackgroundThomaz, D. Y. (2019) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2019.tde-13022019-163819 · Cited by 1
A atividade imunomoduladora de ArtinM sobre o curso da infecção por Cryptococcus gattii
Brito, P. K. M. O. (2019) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.17.2019.tde-30052019-151910 · Cited by 1
Meningitis and Meningoencephalitis
Bodman, A., & Hall, W. A. (2019) · Springer eBooks · doi:10.1007/978-3-030-06088-6_17 · Cited by 1
Steenwyk, J. L., Mead, M. E., Knowles, S. L., Raja, H. A., Roberts, C. D., Bader, O., Houbraken, J. A. M. P., Goldman, G. H., Oberlies, N. H., & Rokas, A. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.04.09.033902 · Cited by 1
“Fungi from the genus Aspergillus are responsible for a considerable fraction of this burden, accounting for more than 250,000 infections annually with high mortality rates (Bongomin et al., 2017).”
BackgroundAção imunomoduladora de vesículas extracelulares produzidas por Aspergillus flavus
Brauer, V. S. (2020) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.17.2020.tde-07092020-102302 · Cited by 1
de Oliveira, G. P., de Sousa, H. R., Gorgonha, K. C. D. M., Borges, T. K. D. S., Rangel, K. T., Fabricant, S. A., Gustavo, F. C. K., Friaça, L. F., Neto, A. R., Hurtado, F. A., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.10.30.362681 · Cited by 1
“5 million people die every year from systemic fungal infections[23].”
BackgroundBiocontrol of Aspergillus niger in 3D-lung cell tissues by oxalotrophic bacteriaPreprint
Palmieri, F., Palmieri, I., Noormamode, N., Estoppey, A., Ishak, M. O., Kelliher, J. M., Vallat, A., Iyer, R. S., Bindschedler, S., Davenport, K. W., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.20.259929 · Cited by 1
“Fungal diseases are estimated to kill more than 1.5 million people every year, with the number of affected patients expected to increase even further (Bongomin et al., 2017; Fisher et al., 2020).”
BackgroundInfluentialSAKrificing an Essential Stress-Sensing Pathway Improves Aspergillus fumigatus Germination
Hérivaux, A., Goldman, G. H., & Papon, N. (2022) · mSphere · doi:10.1128/msphere.00010-22 · Cited by 1
“range of acute and chronic diseases, affecting several millions of people worldwide (1).”
BackgroundDiagnosis of Fungal Infections
Buitrago, M. J., & Valero, C. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-809633-8.20712-7 · Cited by 1
Sialophorin is an essential host element for vaccine immunity against pulmonary fungal infectionsPreprint
Mudalagiriyappa, S., Deepe, G. S., & Nanjappa, S. G. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.31.486552 · Cited by 1
“The increasing immunosuppressed population, including those with CD4+ T-cell deficiency, has elevated the incidence and severity of fungal infections in recent years [1-3].”
BackgroundEpidemiology of Infections Caused by Molds
Cuellar‐Rodríguez, J., & Ostrosky-Zeichner, L. L. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-809633-8.21006-6 · Cited by 1
Gil, F., Laiolo, J., Bayona-Pacheco, B. L., Cannon, R. D., Ferreira‐Pereira, A., & Carpinella, M. C. (2022) · Research Square · doi:10.21203/rs.3.rs-1764979/v1 · Cited by 1
Rai, M. N., Parsania, C., & Rai, R. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4184589 · Cited by 1
Diagnostic Capacity for Fungal Infections in Advanced HIV Disease in Africa: A Continent-Wide SurveyPreprint
Lakoh, S., Kamudumuli, P. S., Penney, R. O. S., Haumba, S., Jarvis, J. N., Hassan, A. J., Moudoute, N. L. E., Ocansey, B. K., Izco, S., Kipkerich, S., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4181706 · Cited by 1
Self-citationKischkel, B. (2022) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.42.2022.tde-13102022-121545 · Cited by 23
Valero, C., Mcmanus, M., Durai, A. R. A., Tindale, J., Gago, S., & Bromley, M. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.05.20.539046 · Cited by 1
Self-citationPalmieri, F., Magnin, M., Diserens, J., et al. (2023) · Preprints.org · doi:10.20944/preprints202305.2247.v1 · Cited by 1
Doorley, L. A. (2023) · doi:10.21007/etd.cghs.2023.0620 · Cited by 1
Fungi in a One Health PerspectivePreprint
Simões, D., de Andrade, E., & Sabino, R. (2023) · Preprints.org · doi:10.20944/preprints202306.1265.v1 · Cited by 1
Fungal infections in Sudan: an underestimated health problemPreprint
Ahmed, S. A., Ismail, M., Albirair, M. T., Nail, A. M. A., & Denning, D. W. (2023) · medRxiv · doi:10.1101/2023.06.20.23291647 · Cited by 2
Self-citationLiu, L., Wu, H., Long, Y., et al. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4502373 · Cited by 1
Simmons, B., Rhodes, J. L., Rogers, T. R., Talento, A. F., Griffin, A., Mansfield, M., Sheehan, D. F., Abdolrasouli, A., Verweij, P. E., Bosch, T., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.07.21.550109 · Cited by 1
Cohen, D. G., & Wingert, R. A. (2023) · Tissue Barriers · doi:10.1080/21688370.2023.2257110 · Cited by 1
Cholera comes to Portugal: Myth and science during the 1833-1834 epidemic and beyondPreprint
Davis, I. (2023) · doi:10.33774/coe-2023-nlfvx · Cited by 1
Candida spp. suppress neutrophil reactive nitrogen species to evade killingPreprint
Burgess, T. B., Hammond, F. R., Szkuta, P. T., Lewis, A., Christou, S., Bowden, K. A., Bicanic, T., Prince, L. R., Ayscough, K. R., Partridge, D. G., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.11.02.565128 · Cited by 1
Azole resistance: Insights from Y132 substitutions in Candida sterol 14α-demethylasePreprint
Rao, R. S. P., Pinto, L., Suravajhala, R., Shenoy, B. D., & Ghate, S. D. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.11.13.566813 · Cited by 1
Aspergillus dsRNA virus drives fungal fitness and pathogenicity in the mammalian hostPreprint
Rocha, M. C., Lerer, V., Adeoye, J. A., Hayby, H., Fabre, M. L., Barber, A. E., & Shlezinger, N. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.16.580674 · Cited by 2
“Furthermore, epidemiologists anticipate a consistent rise in IFI cases due to the growing population of individuals with compromised immune systems 2 .”
Strain heterogeneity in a non-pathogenic fungus highlights factors contributing to virulencePreprint
Rinker, D. C., Sauters, T. J. C., Steffen, K., Gumilang, A., Raja, H. A., Rangel‐Grimaldo, M., Pinzan, C. F., de Castro, P. A., dos Reis, T. F., Delbaje, E., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.08.583994 · Cited by 1
Aspergillus dsRNA virus drives fungal fitness and pathogenicity in the mammalian hostPreprint
Shlezinger, N., Lerer, V., Rocha, M., Adeoye, J. A., & Hayby, H. (2024) · Research Square · doi:10.21203/rs.3.rs-3961709/v1 · Cited by 1
Hidden allies: Decoding the core endohyphal bacteriome of Aspergillus fumigatusPreprint
Piontkivska, D., Jorge, J. M. P., Mil‐Homens, D., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4912975/v1 · Cited by 1
Mechanisms of Resistance to Antifungal Agents
Perlin, D. S. (2023) · Wiley eBooks · doi:10.1002/9781683674849.mcm0134 · Cited by 1
Karadzas, M. T., Michel, A. H., Mosbach, A., Giannakopoulos, G., McGettigan, R., Scalliet, G., & Kornmann, B. (2025) · eLife · doi:10.7554/elife.105333.1 · Cited by 1
Palmieri, F., Trompette, A., Shanmuganathan, A., Bouchard, A., Pernot, J., Junier, T., Kelliher, J. M., Chain, P. S. G., Harris, J. F., Vallat, A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.27.645790 · Cited by 1
Compound Z247611722 Exhibits Antifungal Activity by Inhibiting Serine Palmitoyltransferase
Nysten, J. V., Eynde, W. V., Lee, Y., Vanhoffelen, E., Desiderati, G., Win, T. V., Velde, G. V., Voet, A. R. D., Robbins, N., Cowen, L. E., et al. (2026) · Nature Communications · doi:10.21203/rs.3.rs-6810020/v1 · Cited by 1
Epidemiology of Aspergillosis Diagnoses in the U.S. using a National EHR Database, 2013-2023Preprint
Bustamante, B. L. M., Martinez, E. G., Lee, A., Kane, N. J., Camponuri, S. K., Reynolds, R. M., Snow, T. T., Bartels, J. G. E., Hoffman, M. A., White, T. C., et al. (2025) · medRxiv · doi:10.1101/2025.06.19.25329882 · Cited by 1
mSphere of Influence: Diagnosis of antifungal tolerance and persistence
Chen, L. (2025) · mSphere · doi:10.1128/msphere.00029-25 · Cited by 1
“H uman pathogenic fungi affect approximately 1.7 billion people worldwide, causing conditions from superficial infections to life-threatening invasive diseases (1, 2).”
InfluentialOptimisation du traitement préventif et curatif de la mucormycose pulmonaire
Brunet, K. (2020) · theses.fr (ABES) · doi:10.70675/1367c1e7zd412z4f2ez9be3zb15a2d64bb30 · Cited by 2
Schikora-Tamarit, M. À., López‐Peralta, E., Roldán, A., de Armentia, C., Torres-Cano, A., Alcázar‐Fuoli, L., CAPAR Study Group, Zaragoza, O., & Gabaldón, T. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.18.725882 · Cited by 1
Espinel‐Ingroff, A., Sanguinetti, M., & Posteraro, B. (2019) · Current Fungal Infection Reports · doi:10.1007/s12281-019-0336-2
“The CLSI itraconazole ECVof 1 μg/ml (97”
BackgroundInfluentialRisk Factors of Renal Aspergillosis in Pigeons (Columba livia): Field Study
Palgunadi, B. U., Kurniasih, K., & Prakoso, Y. A. (2019) · American Journal of Animal and Veterinary Sciences · doi:10.3844/ajavsp.2019.78.85 · Cited by 1
Antunes, F. M. A. (2019) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.5.2019.tde-05062019-092951
Ferling, I., Dunn, J. D., Ferling, A., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/730879
“Over 200,000 life-threatening infections are caused by A. fumigatus annually, with mortality rates of infected individuals ranging from 30-90% (Brown et al., 2012, Bongomin et al., 2017).”
BackgroundAn Investigation into Clinically Relevant Determinants of Azole Resistance in Candida albicans
Nishimoto, A. T. (2019) · doi:10.21007/etd.cghs.2019.0486
“Global estimates suggest that invasive candidiasis occur in ~700,000 cases which clearly exceeds ~250,000 cases of invasive aspergillosis (10).”
BackgroundNatesan, S. K., & Chandrasekar, P. H. (2019) · Springer eBooks · doi:10.1007/978-981-13-9459-1_22 · Cited by 1
The role of genital tract infection inpreterm delivery: aretrospective study
Satria, Y. A. A., Budihastuti, U. R., & Susilawati, T. N. (2019) · Journal of the Medical Sciences (Berkala Ilmu Kedokteran) · doi:10.19106/jmedsci005103201904
“Platelet count (x 109/L) 245 (31-589) 211 (17-498) 0.”
Issues and Concerns in the Management of Systemic Candidiasis
Fong, I. W. (2020) · Springer eBooks · doi:10.1007/978-3-030-36966-8_11
Assessment of Azole Resistance in Healthcare Facilities
Caetano, L. A., Costa, N. A., & Oliveira, C. V. D. S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-809633-8.21351-4
Influência de galectina-3 no curso da infecção por Cryptococcus neoformans
Rezende, C. P. (2020) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.17.2020.tde-19092019-125830 · Cited by 2
Sharikadze, O., & Okhotnikova, О. M. (2020) · Pathologia · doi:10.14739/2310-1237.2020.1.203744
“ua and Clinical Immunology, 136(2), 312-322.”
Roden, A. C. (2020) · Cambridge University Press eBooks · doi:10.1017/9781316823040.017
Chronic granulomatous ‘Aspergillus lung mass’
Venkatnarayan, K., Devaraj, U., Krishnaswamy, U. M., Ramachandran, P., Balasundaram, S., Ananthamurthy, A., & Savio, J. (2020) · Monaldi Archives for Chest Disease · doi:10.4081/monaldi.2020.1371
“There has been an exponential increase in the burden of fungal infections in the recent years owing to an increase in the ‘at-risk’ population [1,2].”
BackgroundRoeske, K., Kuryłek, A., Cieślik, J., Wróblewska, M., & Jagielski, T. (2020) · Postępy Mikrobiologii - Advancements of Microbiology · doi:10.21307/pm-2020.59.3.21
Rosiana, S., Zhang, L.-Y., Kim, G. H. E., Revtovich, A. V., Sukumaran, A., Geddes-McAlister, J., Kirienko, N. V., & Shapiro, R. S. (2020) · bioRxiv · doi:10.1101/2020.10.22.350991
“Fungal pathogens have been emerging as a significant threat to human health, resulting in over 1.6 million deaths worldwide each year (Denning 2017; Bongomin et al. 2017; Geddes-McAlister and Shapiro 2019).”
BackgroundInfluentialThe Comparison Between Risk Factors of Invasive Candidiasis and 1,3-β-D-Glucan in Septic Pneumonia
Agustina, D. R. E., Setyawan, U. A., & Sartono, T. R. (2020) · Jurnal Respirologi Indonesia · doi:10.36497/jri.v40i4.132
1,3-Β-D-GLUCAN IN IFI DIAGNOSTICS
Pleško, S., Novak, M., Bilić, E., Vranješ, V. R., Babel, J., Baronica, R., & Mareković, I. (2019) · Liječnički vjesnik · doi:10.26800/lv-141-3-4-14
Pilzinfektionen in der Intensivmedizin
Richter, D., Lichtenstern, C., Brinkmann, A., & Weigand, M. A. (2020) · Intensivmedizin up2date · doi:10.1055/a-1067-2797
“[7] Bongomin F, Gago S, Oladele R et al.”
BackgroundDanao, K. R., Kohadkar, P. B., Mahapatra, D. K., & Mahajan, U. (2020) · International Journal of Current Research and Review · doi:10.31782/ijcrr.2020.122319
Infectious Diseases: Non-Specific and Specific Infections
Biehler‐Gomez, L., & Cattaneo, C. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-85162-6.00003-9
Analysis of regulatory T lymphocytes in fungal infections
Popov, S. V., Shmelkov, I. Y., & Khaidukov, S. V. (2021) · Medical Immunology (Russia) · doi:10.15789/1563-0625-aor-2047
Melhoramento da estabilidade física do pró-fármaco 5-Fluorocitosina via cocristalização
Souza, M. S. (2019) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.76.2019.tde-07052019-110715 · Cited by 1
Hafezi, F. (2020) · touchREVIEWS in Ophthalmology · doi:10.17925/usor.2020.13.2.55
“bacterial and fungal).(14) This is compounded by increasing antimicrobial resistance, reducing our armamentarium of effective drugs.”
BackgroundPilzinfektionen in der Intensivmedizin
Richter, D., Lichtenstern, C., Brinkmann, A., & Weigand, M. A. (2021) · Krankenhaushygiene up2date · doi:10.1055/a-1338-9359
“[7] Bongomin F, Gago S, Oladele R et al.”
BackgroundPositron emission tomography in infections associated with immune dysfunction
Ankrah, A. O. (2020) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.144628960
Introductory Chapter: The Global Distribution of Human Histoplasmosis - An Overview
Bongomin, F., & Nsenga, L. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.92981
Self-citationMcKloud, E., Sherry, L., Kean, R., Delaney, C., Williams, S., Metcalfe, R., Thomas, R., Williams, C., & Ramage, G. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.12.430906
Developing effective amphotericin B delivery systems for fungal infections
de Paula, R. C. M., Richter, A. R., Paula, H. C. B., & Feitosa, J. P. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821100-7.00002-9
Achan, B., Mboowa, G., Kwizera, R., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-311293/v1
Self-citationThe importance of mucormycosis infections on example of Rhino Orbital Cerebral Mucormycosis
Pałka, Ł., & Gaur, V. (2021) · Postępy Higieny i Medycyny Doświadczalnej · doi:10.5604/01.3001.0014.8123
A Syk/CARD9 szignalizáció szerepe a Candida parapsilosis immunológiai felismerésében
Zajta, E. (2020) · SZTE Repository of Dissertations (University of Szeged) · doi:10.14232/phd.10576
Swidergall, M., Solis, N. V., Wang, Z., et al. (2018) · SSRN Electronic Journal · doi:10.2139/ssrn.3299434
Human Mycobiome In Normobiosis And Dysbiosis States Characteristics And Analysis Methods
Gnat, S., Łagowski, D., Dyląg, M., & Nowakiewicz, A. (2021) · Postępy Mikrobiologii - Advancements of Microbiology · doi:10.21307/pm-2021.60.1.04
RetractedInteraction between the opportunistic pathogen Aspergillus fumigatus and its host
Keizer, E. (2021) · Utrecht University Repository (Utrecht University) · doi:10.33540/632
Machumi, F., Innocent, E. M., & Pius, Y. (2021) · Journal of Medicinal Plants Research · doi:10.5897/jmpr2020.7056
“Fungal diseases affect more than a bilion people worldwide, mostly in the tropic and subtropic regions (Bongomin et al., 2017).”
BackgroundDinas, P. C., Domanović, D., Koutedakis, Y., Hadjichristodoulou, C. S., Stefanidis, I., Papadopoulou, K. Κ., DIMAS, K. S., Perivoliotis, K., Tepetes, K., & Flouris, A. D. (2021) · JMIR Research Protocols · doi:10.2196/25674
“The safety interventions are essential given a steady increase in transplantations of human tissues and cells [3] and transfusion of blood and blood components [4].”
ESQUISTOSSOMOSE: TRANSMISSÃO E ESTRATÉGIAS DE CONTROLE EM ÁREAS ENDÊMICAS
Ribeiro, E. C. G., & Coutinho, D. F. (2021) · Amplla Editora eBooks · doi:10.51859/amplla.dip344.2121-14
Njovu, I. K., Musinguzi, B., Mwesigye, J., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-523551/v1
Brackin, A. P., & Shah, A. (2021) · doi:10.14293/icmb210010
PULMONARY ARTERIAL HYPERTENSION IN ADULT-ONSET STILL'S DISEASE: A CASE SERIES OF 13 PATIENTS
Mitrovic, S., Boucly, A., Lazaro, E., SCHLEINITZ, N., Bloch‐Queyrat, C., Christides, C., Pouchot, J., Humbert, M. J. C., Montani, D., Savale, L., et al. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-eular.2668 · Cited by 1
Brain Infections, Encephalitis, and Meningitis: Fungus
Generoso, J. S., Collodel, A., Hasbun, R., & Barichello, T. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-818731-9.00126-9
Melinda, M. A., & Mahendra, A. N. (2021) · Jurnal Epidemiologi Kesehatan Komunitas · doi:10.14710/jekk.v6i1.9562
Avaliação da produção e composição de vesículas extracelulares de Aspergillus fumigatus
Pessoni, A. M. (2021) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.17.2021.tde-08092021-112744
Brown, A. C., Mead, M. E., Steenwyk, J. L., Goldman, G. H., & Rokas, A. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.10.26.465918
“Invasive aspergillosis (IA), a human disease caused by members of the fungal genus Aspergillus, is responsible for >400,000 cases worldwide per year with a mortality rate between 50-95% (Bongomin et al., 2017).”
BackgroundKhatri, A., Prasai, G., Pandey, M., Kharel, M., Bohara, D., Panthi, M., Thapa, N., Jha, B., & Pradhan, E. (2021) · Nepalese Journal of Ophthalmology · doi:10.3126/nepjoph.v13i2.39751
“Even prior to the COVID-era, the Leading International Fungal Education portal had estimated an international prevalence of 10,000 cases excluding India that astonishingly reached 910,000 when cases in India were included (Chakrabarti, A. and Dhaliwal, M., 2013; Bongomin et al, 2017).”
BackgroundBorderline microscopic organism and lockdown impacted across the borders—global shakers
Suleman, S., Farooqui, A., Sharma, P., Malhotra, N., Yadav, N., Narang, J., Hasnain, M. S., & Nayak, A. K. (2021) · Environmental Science and Pollution Research · doi:10.1007/s11356-021-17641-w · Cited by 1
“Worldwide, a large number of viral, bacterial and fungal epidemics have been reported (Bongomin et al. 2017).”
Background宮脇, 真. (2002) · 江戸文学
Косей, Н. В., Regeda, S. I., Glamazda, M., & Васильченко, Л. А. (2021) · Reproductive Endocrinology · doi:10.18370/2309-4117.2021.61.77-82
Metadata
- Authors
- Bongomin, F., Gago, S., Oladele, R., & Denning, D.
- Affiliations
- University of Manchester (GB)
- Corresponding author
- Denning, David
- Venue
- Journal of Fungi
- Publisher
- MDPI AG
- Published
- 2017-10-18
- Volume
- 3
- Issue
- 4
- Pages
- 57
- ISSN
- 2309-608X (ISSN-L)
- PMC
- PMC5753159
- OpenAlex
- W2767031614
- Semantic Scholar
- a31bc4c8c2356520b0818d41b5c4a2e2091b6f32
- Cited by
- 2,953
- References
- 192
- Citations by year
- 2026: 280 · 2025: 388 · 2024: 518 · 2023: 436 · 2022: 427 · 2021: 370 · 2020: 307 · 2019: 156 · 2018: 67 · 2017: 2
- FWCI
- 22.27
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Fungi (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC/P002390/1)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Health Sciences › Medicine › Dermatology › Nail Diseases and Treatments
- Keywords
- fungal infection, disease burden estimation, prevalence, chronic pulmonary aspergillosis, cryptococcal meningitis, invasive candidiasis, Pneumocystis carinii pneumonia, invasive aspergillosis, disseminated histoplasmosis, fungal asthma, fungal keratitis, HIV/AIDS, antifungal therapy, estimation accuracy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.